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Abstract
Introduction: Immunohistochemistry of primary breast cancer is routinely used to guide changes in therapy at the
time of relapse. Retrospective reviews suggest that the estrogen receptor (ER), progesterone receptor (PR) and
human epidermal growth factor receptor type 2 (HER2) receptor may differ between the primary and loco-regional
recurrence or distant metastases. The Breast Recurrence In Tissues Study (BRITS) was a large, multicentre,
prospective study to examine changes in ER, PR and HER2.
Methods: Matched primary and recurrent breast cancer tissue samples were prospectively collected from 205
women attending 20 institutions. Central laboratory immunohistochemical analysis of core biopsies and tissue
microarrays of ER and PR using the Allred and Quickscore methods and HER2 (confirmed by fluorescence in situ
hybridisation (FISH) for HER2 2+) were performed.
Results: From 205 consenting women, 18 (8.8%) did not have recurrent disease on biopsy, 35 were ineligible,
13 had insufficient paired tissue and 2 were excluded for safety reasons. Paired samples from 137 women, mean
age 62.6 years (range 27-87 years), 83/137 (60.6%) postmenopausal with a median 92.2 months (range 5-327
months) from primary to recurrence and 88 (64.2%) as locoregional recurrence were successfully analysed. A switch
in receptor status, in either direction, by Allred score, was identified for ER in 14 patients (10.2%; P = 0.983
Wilcoxon sign rank test), PR in 34 (24.8%; P = 0.003 Wilcoxon sign rank test) and HER2 in 4 (2.9%; P = 0.074
Wilcoxon sign rank test). There was no difference between locoregional or distant recurrence in the proportion
who switched. The switch in receptor status led to a change in the subsequent treatment plan for 24 patients
(17.5%).
Conclusions: This prospective study confirms retrospective evidence that the management of relapsed breast
cancer should include confirmatory tissue sampling and identify switches of ER, PR or HER2 which change
therapeutic management for one in six patients.
Introduction
The management of recurrent breast cancer requires evi-
dence-based approaches [1] since the median survival in
patients with overt metastatic disease is 20 months [2].
Current opinion supports reassessment of estrogen
receptor (ER), progesterone receptor (PR), and human
epidermal growth factor type 2 (HER2) receptor in tumor
tissue at the time of diagnosis of relapse to tailor appro-
priate therapy for each patient [3,4]. This is based largely
on retrospective evidence that loss of ER in recurrent
breast cancer [5] is an established predictor for poor
response to endocrine therapy [6].
H i s t o r i c a l l y ,E R ,P R ,a n dH E R 2 ,w h e r ea v a i l a b l ef r o m
the primary cancer, have been used to direct subsequent
therapy, assuming no change in the biological features of
the recurrent disease compared with the original primary;
this approach is no longer considered tenable [3,4].
Although molecular approaches have been used with
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cancer [7-9], such transcriptome approaches have yet to
be validated in the context of recurrent disease.
Studies of paired samples of the primary tumor and
locally/regionally recurrent or distant metastases suggest
that tumor receptor status may be discordant in a signif-
icant proportion of patients: 18% to 54% for ER, 36% to
54% for PR, and 3% to 22% for HER2 in both retrospec-
tive series [6,10-14] and small prospective series [15-17].
Routine diagnostic histopathology and immunohisto-
chemistry (IHC) of recurrent breast cancer for ER, PR,
and HER2 (with fluorescence in situ hybridization [FISH]
testing of HER2 where appropriate) may be a pragmatic
solution to ensure that the patient actually has recurrent
breast cancer [17] and to guide further patient therapies.
The Breast Recurrence In Tissues Study (BRITS) sought
to establish the value of these established diagnostic
approaches in a prospective, multicenter evaluation. The
BRITS set out to quantify the percentage of tumors that
changed receptor status (positive to negative or negative
to positive) for ER, PR, and HER2 expression between
the original and recurrent tumor in women with breast
cancer and to determine the proportion of patients in
which a switch in ER, PR, or HER2 led to a change in the
subsequent treatment plan.
Materials and methods
Women who had a history of invasive breast cancer and
who were willing to consent to biopsy of recurrent dis-
ease (locoregional or distant metastasis) were invited to
participate in the BRITS during 2007-2008 at 20 second-
ary care sites in the UK. Multicenter ethics permission
for the BRITS was obtained through the North Glasgow
Ethics Research Committee. Breast cancer in a conserved
breast was pragmatically considered to be recurrence
rather than a new primary cancer, but contralateral pri-
mary invasive cancer was excluded. Two hundred five
women provided written informed consent to prospec-
tively participate in order to supply 137 good-quality
paired tumor samples (Figure 1).
Patients were required to have available a formalin-
fixed paraffin-embedded (FFPE) tumor from both the
primary cancer and the recurrence to be fully evaluable.
FFPE tissue at the time of recurrent breast cancer was
biopsied (as a core biopsy or resected tissue) and diag-
nostic review was conducted by the local pathologist to
confirm the presence of invasive breast cancer. FFPE
from the primary cancer was subsequently retrieved
from the local pathology department, paired with the
prospectively collected recurrent breast cancer FFPE
block, and sent for central specialist pathologist review
by CAP and LBJ.
Central pathology review comprised new full-face
hematoxylin and eosin (H&E) section of all specimens
to confirm the presence of sufficient, suitably fixed inva-
sive breast cancer in both primary and recurrent speci-
mens. All patients had a full-size tissue block from the
original primary cancer; excisional tissue was available
from the recurrent disease of 100 patients (73%), and
core biopsy only was available from 37 women (27.0%).
Blocks were marked for tissue microarray (TMA) con-
struction of 6 × 0.6 mm cores of invasive cancer TMA
(Beecher Instruments, Sun Prairie, WI, USA). Thus, in
Figure 1 Consort diagram of the Breast Recurrence In Tissues
Study (BRITS).
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structed into TMA blocks, whereas in 37 patients, the
TMA of the primary was compared with full-face
sections of core biopsies of the recurrent disease.
Immunohistochemistry
Immunohistochemical staining was carried out on 4-μm
sections of FFPE TMAs or full sections of cores with the
mouse monoclonal anti-ER-alpha antibody 6F11 1:200
(Novocastra Laboratories Ltd, Newcastle-upon-Tyne,
UK), PR antibody clone 16, 1:800 (Novocastra Labora-
tories Ltd), and a mouse monoclonal anti-HER2 antibody
CB11 (Novocastra Laboratories Ltd) as primary antibody.
Negative controls (lacking primary antibody) were per-
formed for all samples stained. Antigen retrieval for ER
and PR was carried out using a microwave/pressure ves-
sel followed by processing on a DAKO TechMate™
500 Plus autostainer (Dako, Glostrup, Denmark) with the
DakoREAL™ detection system (an indirect streptavadin/
biotin method using anti-mouse antibody) and visualized
with horseradish peroxidase and diaminobenzadine.
ER and PR status was assessed by means of two meth-
ods: primarily the Allred score [18], which is used as a
current worldwide standard for ER and PR reporting,
and the ‘Quickscore’ method, which examines both the
intensity and proportion of cells stained [19]. With the
Allred score, tumors scoring 0 or 2 were regarded as
negative from the point of view of endocrine therapy,
whereas cases scoring at least 3 were regarded as posi-
tive. HER2 scoring was carried out with the standard
negative (0), negative (1+), equivocal (2+), and positive
(3+) system [20].
TMA and full-section immunohistochemical staining
conducted in this laboratory (as described) demonstrates
concordance of IHC scoring for ER, PR, and HER2 [21].
Indeed, just two 0.6-mm cores, rather than the six used
here, may be sufficient to represent staining seen on an
entire histological section, even for markers generally
thought to be heterogenous [21]. For all IHC, investiga-
tors were blinded, where possible, to the clinical data.
Clearly, core biopsy samples could be from recurrent
breast cancer only; cases that were difficult to score
were subject to consensus reporting by LBJ and CAP on
a multi-headed microscope.
HER2
HER2 amplification was assessed in the nationally accre-
dited regional cytogenetics laboratories as previously
described [20]. Briefly, FISH was conducted using a locus-
specific probe (Qbiogene Inc., MP Biomedicals Europe, Ill-
kirch, France) on full-face or core biopsy sections that
were 4 μm thick. All HER2 slides were viewed using an
Olympus BX51 epi-fluorescence microscope (Olympus,
Tokyo, Japan) equipped with DAPI, SpectrumGreen™,a n d
SpectrumOrange™ filter cubes. Images were captured by
means of Applied Spectral Imaging acquisition software
(Edingen, Germany). The ratio of orange (HER2) to green
(CEP17) signals (PathVysion Her2 assay; Vysis, Inc.,
Downers Grove, IL, USA) was calculated for all of the
cases studied. A ratio of at least 2.0 was counted as ampli-
fied. At least 10 non-overlapping nuclei were scored for
amplified tumors.
HER2-positive cancers were thus defined as those that
were IHC 3+ (all of which were also amplified by FISH)
or HER2 2+ and FISH-amplified (all but one of the
HER2 2+ cancers had amplification using FISH). Redefi-
nition of the cutoff for amplification of at least 2.2 did
not alter the categorization of the cancers as no ampli-
fied tumors had a FISH amplification ratio of between
2.0 and 2.2.
Statistical analysis
Sample size was determined prior to commencement of
the study by using the percentage of subjects switching
ER status (ER-positive to ER-negative or ER-negative to
ER-positive) from primary to recurrence as the primary
endpoint. On the basis of published retrospective data
available at the time of study design (including [6,10,12]),
a conservative assumption was made that if 10% of sub-
jects switched ER status between the initial biopsy and
the biopsy taken at recurrence, a sample size of 139 fully
evaluable subjects would yield a 95% confidence interval
(CI) with a width of ± 5% to detect a significant differ-
ence in ER.
The statistical significance of the change in ER, PR,
and HER2 score was analyzed by means of one sample
student test (95% CIs and P v a l u e ) .T oa l l o wf o rt h e
potential that data were not normally distributed, the
t test was replaced with the Wilcoxon sign rank test,
median differences, the associated CIs, and the P value.
Associations between the original sample score and the
change in the ER, PR, and HER2 expression scores, as
measured by IHC or FISH between the original and
recurrent samples, were considered using the Pearson
correlation coefficient (if data were assumed to be con-
tinuous) and, in keeping with clinical decision making
(considering ER, PR, and HER2 to be positive or nega-
tive), the Spearman correlation coefficient. The associa-
tion between the switch in status of ER, PR, and HER2
and primary tumor size (defined in ordered categories),
grade of tumor (1, 2, 3), node status, and the Notting-
ham Prognostic Index were investigated by the
chi-square test (with degrees of freedom and the asso-
ciated P value). The categories of each variable were
summarized and presented as frequency and percentage.
Logistic regression analyses were performed to deter-
mine the association between switching status in ER, PR,
and HER2, the time between diagnosis and recurrence
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for breast cancer. The differences between groups were
summarized by the odds ratio (odds that the subject
switched status with respect to an additional previous
breast cancer treatment or an additional unit time
between diagnosis and recurrence, respectively), asso-
ciated 95% CIs, and P value.
Results
From 205 women who consented to the BRITS (Figure 1),
18 (8.8%) did not have recurrent malignancy on biopsy (or
indeed recurrence elsewhere), despite an initial clinical
diagnosis of disease relapse. Nine patients had insufficient
primary or recurrent tissue for study on review of the tis-
sue blocks, 35 women were incorrectly enrolled, and
2 withdrew because of safety concerns (regarding biopsy).
For the 137 women with paired primary and recurrent tis-
sue samples, the mean age at disease recurrence was 62.6
years (standard deviation of 12.3 years), median age was
63.0 years, and range was 27 to 87 years. All but two
women were Caucasian, and 83 out of 137 subjects
(60.6%) were postmenopausal. The mean time to first
recurrence of breast cancer following completion of pri-
mary therapy was nearly 8 years (93.2 months), and the
mean time from original tissue sampling to the biopsy
used for the BRITS was 9 years (106.7 months; range of
5 to 327 months). Previous therapies included endocrine
therapy for 100 out of 136 (73%) (1 patient not known),
previous chemotherapy for 62 (45.3%) (2 patients not
known), and previous radiotherapy in 108 (78.8%)
(1 patient not known). There were no significant differ-
ences in demographic features between the 137 women
included in the analyses and the 68 women excluded.
Seventy-two out of 137 subjects (52.6%) had a lum-
pectomy and 47 (34.3%) a mastectomy at the time of
the original primary diagnosis (7 patients not recorded).
A further 11 subjects (8.0%) had a lumpectomy followed
by completion mastectomy. The majority of patients had
within-breast (44.5%) or regional soft tissue/locoregional
(19.7%) disease recurrence (Table 1).
Pathology type
For the original primary cancer pathology subtype, 96
out of 137 subjects (70.1%) had invasive ductal cancer,
23 lobular, 10 tubular/cribriform, 4 mucinous, and 2
medullary, and 2 had missing data. In addition, 84 sub-
jects (61.3%) had in situ carcinoma: 74 (88.1%) ductal
carcinoma in situ (DCIS) and 8 (9.5%) lobular carci-
noma in situ. No recurrent cancers demonstrated a
change in subtype.
Changes in estrogen receptor and progesterone receptor
Central laboratory analysis of the original primary can-
cer was ER-positive by Allred score in 109 out of 137
subjects (79.6%), PR-positive by Allred score in 85 sub-
jects (62.0%), and HER2-positive in 14 subjects (10.2%)
(Table 2). Central laboratory analysis of the recurrent
breast cancer demonstrated that the ER staining was
positive in 101 (73.7%), PR was positive in 75 (54.7%),
and HER2 was positive in 16 subjects (11.7%).
With the Allred scoring, a switch in receptor status
(Table 2) was identified for ER in 14 patients (10.2%):
from ER-positive to ER-negative in 11 patients (8.0%) and
from ER-negative to ER-positive in 3 (2.2%). A change
in PR was noted in 34 cancers (24.8%): PR-positive to
PR-negative in 22 patients (16.1%) and PR-negative to
PR-positive in 12 (8.7%) in the recurrent biopsy. An addi-
tional 3 patients (2.2%) became HER2-positive, and 1
patient went from HER2-positive to HER2-negative.
The histological sections stained for ER or PR and
rescored using the Quickscore method blinded to the
Allred score demonstrated a difference in endocrine
receptor switch compared with the Allred score in
13 patients (Table 2): from ER-positive to ER-negative
(2) or ER-negative to ER-positive (1) and a switch from
PR-positive to PR-negative (10) but not PR-negative to
PR-positive (0). In keeping with the literature [21-23],
where full-face sections were available and compared
with TMA data for ER and PR, no differences in scoring
were identified.
HER2
Few patients (14, 10.2%) were HER2-positive at the time of
primary diagnosis; 4 patients (2.9%) gained (3 patients) or
lost (1 patient) HER2-positive tumor staining (Table 2),
although this failed to achieve statistical significance for
a change in HER2 receptor scores (P = 0.074). Most
patients ( > 80%) were HER2-negative on both occasions.
Clinical impact
A switch in ER, PR, or HER2 receptor status (positive to
negative or negative to positive) overall occurred in 34 out
of 137 patients (24.8%). The combination of ER and PR
was used to guide the use of endocrine agents. Thus, in
the opinion of the accruing clinicians at the recruiting cen-
ters, this change in receptor status (in either direction) led
to a change in the planned next treatment for the relapsed
breast cancer in 24 out of 137 women (17.5%): 20 based
Table 1 Sites of breast cancer recurrence
Site of recurrent
disease
Number of
patients
(total = 137)
Percentage of
patients
Locoregional disease 88 64.2%
Distant soft tissues 16 11.7%
Other distant metastasis 33 24.1%
Thompson et al. Breast Cancer Research 2010, 12:R92
http://breast-cancer-research.com/content/12/6/R92
Page 4 of 9on endocrine receptor and 4 based on HER2 receptor
changes (Table 3).
Comparison between locoregional recurrence and dis-
tant metastasis failed to identify a significant difference
for changes in ER, PR, or HER2 (Table 4). There was no
significant difference between subjects who switched ER,
PR, and/or HER2 status and the number and type of
previous treatments (including endocrine treatments)
for breast cancer, the time between diagnosis and recur-
rence, the tumor size, grade of tumor, node status, or
the Nottingham Prognostic Index derived from the pri-
mary cancer.
Discussion
In contrast to the diagnosis of primary disease, biopsy of
relapsed, locoregional, or distant metastatic breast can-
cer is not widely established in routine clinical practice,
despite evidence suggesting that such a biopsy may
influence patient management [3-5,14,17]. The historical
default position for therapeutic decision making has
been based on the IHC of the primary tumor, and the
IHC may or may not reflect the relapsed disease.
The BRITS reports the largest, prospective, multicen-
ter study of primary versus recurrent locoregional or
metastatic breast cancer to date. The demographic
considerations of the patients participating were repre-
sentative of women with symptomatic breast cancer at
presentation [1]. However, despite commitment from 20
centers, 68 patients were lost from the 205 initially
recruited, including 18 patients (8.8%) with clinical mis-
diagnosis of recurrent breast cancer, confirming that
biopsy may be necessary to confirm disease recurrence
in up to 10% of patients [17]. Despite the large size of
this prospective study, two potential sources of patient
bias remain. The relatively long duration between the
primary and recurrent disease may favor the later recur-
rence of ER-positive HER2-negative breast cancer,
reflected in the relatively large proportion of high ER-
positive and low HER2-positive cancers. Second, tissue
acquisition of breast, chest wall, or axillary disease (two
thirds of patients in the current study) as part of thera-
peutic completion mastectomy and associated surgery
may fit with routine clinical practice and be more read-
ily achieved than biopsy of distant metastatic disease.
However, no difference in receptor switch with respect
to locoregional or distant site of recurrence was found
(Table 3), confirming a large retrospective review [14].
In keeping with this, autopsy data comparing primary to
multiple metastatic sites suggested that the metastases
were consistent in ER, PR, and HER2 with each other,
Table 2 Changes in estrogen receptor, progesterone receptor, and HER2 receptors
Receptor status of primary Number
(Percentage)
Allred status of recurrence Number
(Percentage)
Quickscore status of recurrence Number
(Percentage)
ER
+ 109
(79.6%)
ER
+ 98
(71.5%)
ER
+ 100
(73.0%)
ER
- 11
(8.0%)
ER
- 9
(6.6%)
ER
- 28
(20.4%)
ER
- 25
(18.2%)
ER
- 24
(17.5%)
ER
+ 3
(2.2%)
ER
+ 4
(2.9%)
PR
+ 85
(62.0%)
PR
+ 63
(46.0%)
PR
+ 53
(38.7%)
PR
- 22
(16.0%)
PR
- 32
(23.4%)
PR
- 52
(38%)
PR
- 40
(29.2%)
PR
- 40
(29.2%)
PR
+ 12
(8.8%)
PR
+ 12
(8.8%)
HER2 status of recurrence Number
(Percentage)
HER2
+ 14
(10.2%)
HER2
+ 13
(9.5%)
HER2
- 1
(0.7%)
HER2
- 123
(89.8%)
HER2
- 120
(87.6%)
HER2
+ 3
(2.2%)
ER, estrogen receptor; HER2, human epidermal growth factor type 2; PR, progesterone receptor.
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nous primary cancer [8].
Through the use of a single central laboratory and con-
sensual reporting by two specialist breast pathologists,
the study methodology has sought to address a number
of technical issues, including the choice of antibody, anti-
body staining conditions, and scoring systems that are
recognized difficulties with IHC [22,23]. The differential
fixation of resected primary cancer compared with core
biopsy has demonstrated the greater ER and PR positivity
in core biopsies [24]. Given that, in the BRITS, cores
were predominantly from distant metastatic lesions, the
better fixation of cores could overestimate the gain of ER
(identified in less than 3%) or PR (identified in less than
9%) identified in a minority of patients (Table 2).
Intratumoral heterogeneity, potentially generating sam-
pling errors for both the primary and the recurrence,
cannot be excluded from consideration. However, multi-
ple cores (up to six per primary and six per recurrence)
in excess of the two generally held to be sufficient [21]
were selected by a specialist breast pathologist (CAP or
LBJ) to generate the TMAs, and ER and PR were shown
to be consistent between TMAs using multiple 0.6-mm
cores from each cancer and full sections [21,25]. Then,
attempts were made to minimize technical variables as a
source of bias in reporting this study. The use of FISH,
which has also been validated on TMAs [26], to clarify
the HER2 status of both the primary and recurrent dis-
ease by an accredited cytogenetics service should give
confidence that the progression to HER2 amplification
demonstrated here in 2.2% of cancers accurately reflects
cytogenetic gain in the relapsed disease compared with
the primary cancer.
We considered whether the use of the Allred score
(0 to 8) [18], though in keeping with many current his-
topathology reporting conventions, might be less discri-
minatory (presenting an ‘all or nothing’ result) to detect
Table 3 Therapy change based on receptor status in 24 patients
Primary Recurrence Primary
PR
Recurrence
PR
Primary
ER
Recurrence
ER
Primary
HER2
Recurrence
HER2
Therapy change based
on
Excision Core 7 8 7 8 Positive Negative HER2
Excision Core 7 7 8 8 Negative Positive HER2
Excision Core 7 6 8 8 Negative Positive HER2
Excision Excision 0 0 7 0 Negative Positive ER and HER2
Excision Excision 0 0 7 0 Negative Negative ER
Excision Excision 0 0 3 2 Negative Negative ER
Excision Core 7 3 6 0 Negative Negative ER
Excision Excision 8 0 7 0 Negative Negative ER
Excision Excision 0 0 8 0 Negative Negative ER
Excision Core 2 2 7 0 Negative Negative ER
Excision Excision 5 0 6 2 Negative Negative ER
Excision Excision 0 0 3 0 Positive Positive ER
Excision Excision 4 0 7 0 Positive Positive ER
Excision Excision 0 0 0 7 Negative Negative ER
Excision Excision 0 6 0 8 Negative Negative ER
Excision Excision 0 0 0 7 Negative Negative ER
Excision Excision 6 0 8 2 Positive Positive ER and PR
Excision Excision 4 0 0 0 Negative Negative PR
Core Excision 5 0 0 0 Negative Negative PR
Core Core 6 0 8 7 Negative Negative PR
Excision Excision 6 0 7 7 Negative Negative PR
Excision Excision 7 0 7 7 Negative Negative PR
Excision Excision 7 0 7 7 Negative Negative PR
Excision Excision 4 0 6 5 Negative Negative PR
Comparison of primary and recurrent breast cancer progesterone receptor (PR), estrogen receptor (ER), and human epidermal growth factor type 2 (HER2) with
documented reason for change in subsequent therapy is shown. Receptor status is summarized as negative (-) or positive (+).
Table 4 Change in receptor status by locoregional
or distant recurrence
Receptor Locoregional
recurrence,
number (percentage)
Distant recurrence,
number
(percentage)
Estrogen receptor 9/88 (10.2%) 5/49 (10.2%)
Progesterone
receptor
22/88 (25.0%) 12/49 (24.5%)
HER2 2/88 (2.3%) 2/49 (4.1%)
HER2, human epidermal growth factor type 2.
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tems. The rescoring of the sections (with investigators
blinded to the Allred score) by means of the Quickscore
method (0 to 18) [19], which multiplies cell intensity by
proportion, is generally consistent with the Allred score
but did identify a small number of patients in whom the
ER changes (3) or PR changes (10) were sufficiently dif-
ferent in the Quickscore methodology and consequently
crossed the clinical cutoff for endocrine therapy. Thus,
both quality assurance of histopathology and the scoring
regimens used for immunohistochemical analyses may
impact on the clinical direction provided by histopatho-
logical review of relapsed breast cancer.
Changes in endocrine receptor status
Changes in ER and PR status, though of clinical signifi-
cance in directing changes in therapy, were of borderline
statistical significance regardless of which scoring system
was used, despite the pre-study statistical power calcula-
tions based on the primary endpoint of change in ER.
The changes were in keeping with a recent 25-patient
prospective study [17] and the discordance between the
primary and recurrent disease in up to 36% of patients
for ER and up to 54.2% for PR, and gain was less com-
mon than loss of ER or PR (reviewed in [14]). Further-
more, any distinction between considering ER or PR
switches in the context of locoregional or metastatic dis-
ease may now be less relevant in the light of autopsy
studies [8]. However, patients with concordant ER and
P Ri nt h ep r i m a r ya n dr e l a p s e dt u m o rm a yh a v eas i g -
nificantly better post-recurrence survival than discordant
paired samples [27]. Similar prospective clinical follow-
up in the context of the BRITS was not planned.
HER2
The gain in HER2 in three patients identified here con-
firms prospective evidence that acquisition of HER2
amplification suitable for therapeutic targeting is clini-
cally important [17]. Despite interpretational difficulties
and issues of tumor heterogeneity, most, but not all
[13,28], retrospective series report discordance between
the primary and relapsed disease, usually gain of HER2
[14,29] rather than loss of HER2 [14,30].
Clinical implications
The inclusion of tissue acquisition and analysis into rou-
tine practice in the management of locoregional or dis-
tant metastasis carries implications for the treatment of
relapsed breast cancer. While the time needed to obtain
such a biopsy may raise patient concerns [17], avoiding
misdiagnosis based on clinical opinion in 8.8% (this
study) to 10% [17] of women su p p o r t st i s s u eb i o p s yi n
the absence of imaging techniques sufficiently mature to
replace pathology assessment. Given the consistency
demonstrated between metastases at all sites [8], the site
selected for biopsy and ER, PR, and HER2 analysis may
now be considered less critical than once believed
[31,32]. The resource implicati o n sf o rs u r g i c a lo ri n t e r -
ventional imaging-guided biopsy and pathology assess-
ment of biopsy material need to be balanced with the
more rational use of therapy based on tumor receptor
status.
Although prior therapies were not associated with a
change in receptors [14] (loss of ER or PR was con-
firmed as the most common change in receptor status
[14-17]), changes from ER-negative to ER-positive in
2.2% (by Allred score) and PR-negative to PR-positive in
12 patients (8.8%) were observed. Thus, failure to biopsy
recurrent disease may deny such patients potentially
effective treatment with endocrine therapy.
The clinical impact of these changes in receptor was
reflected by the physicians who accrued patients to this
study and who considered that the information from
ER, PR, and HER2 assessment of the locoregional recur-
rence or metastatic disease would change the therapies
offered in 17% of patients, emphasizing the potential of
biopsy of breast cancer recurrence to positively influ-
ence therapeutic decision making [3,4,16,17]. Whether
similar considerations apply to other epithelial cancers
such as colorectal and ovarian cancer [33,34] is uncer-
tain given the consistency in expression of some pro-
teins between primary and metastasis in these cancer
types.
Conclusions
This large prospective study has demonstrated that the
management of relapsed breast cancer should include tis-
sue sampling to avoid misdiagnosis of 1 in 12 patients, to
confirm the diagnosis of recurrent breast cancer, to iden-
tify switches of ER, PR, or HER2 status in the locally
recurrent or metastatic breast cancer, and to influence
the planned treatment for 1 in 6 patients.
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